Best Tools for Healthcare Private Equity Roll-Ups in 2026

A healthcare roll-up runs on four kinds of software, not one: something to find fragmented practices worth buying, something to track sponsor and deal activity, something to run the pipeline as a CRM, and something to consolidate the books once the add-ons close. Most “best PE tools” lists cover only the first two, aimed at generalist dealmakers rather than a team buying dental, dermatology, or physician-group practices specifically.

Healthcare has its own targeting problem: the best add-ons are often single-location, physician-owned practices that never show up in a generic company database until a broker already has them in market. The tools worth shortlisting in 2026 are the ones built or configured for that kind of fragmented, provider-level sourcing, not just private-markets data with a healthcare filter.

Key takeaways

• Add-on acquisitions made up roughly 65% of the 1,029 US healthcare PE deals tracked in 2025, so a roll-up’s sourcing tool matters more than its buyout tool.

• Healthcare PE deal value hit a record $191 billion globally in 2025, with provider and services deals up 57% year over year.

• Generalist deal-sourcing platforms (Grata, PitchBook) find companies; healthcare-specific data (claims, provider affiliations) finds physicians and practices inside those companies.

• A PE-specific CRM is not optional once a platform company starts doing 10+ add-ons a year — spreadsheets stop holding up around deal five or six.

• Post-close ERP is the most commonly skipped tool on this list, and the one that determines whether month-end close takes 4 days or 20 once a portfolio hits double-digit entities.

Why Healthcare Roll-Ups Are Running at Record Pace

Mostly because the math keeps working: buy a platform at one multiple, buy add-ons underneath it at a lower one, and the arbitrage funds the next deal. Global healthcare private equity hit a record $191 billion in disclosed deal value in 2025, according to Bain & Company’s Global Healthcare Private Equity Report 2026, surpassing the previous high set in 2021, with deal volume the second-highest on record at 445 buyouts. Provider and related-services transactions were a big part of that surge, increasing 57% year over year to an estimated $62 billion.

Most of that activity is not headline-grabbing platform buyouts. In the US specifically, the Private Equity Stakeholder Project tracked 1,029 PE-backed healthcare deals in 2025 — 151 leveraged buyouts, 214 growth investments, and 664 add-on acquisitions spread across 420 platform companies, which means roughly two-thirds of all deal activity was small, serial, tuck-in acquisitions rather than splashy new platforms. That volume of small deals is exactly why sourcing tooling matters more in healthcare roll-ups than in a typical PE sourcing motion: a team doing 15 add-ons a year cannot manually cold-call its way to targets.

The consolidation this produces is measurable at the physician level, too. The share of physicians in PE-owned practices reached 6.5% in 2024, according to the American Medical Association’s Physician Practice Benchmark Report, up from roughly 4.5% in both 2020 and 2022. That number understates the concentration in the specialties roll-ups actually target — dermatology, gastroenterology, ophthalmology, and dental care are all well ahead of the national average — which is part of why finding the remaining independent targets before a competing sponsor does has become the central sourcing problem.

What a Healthcare Roll-Up’s Tool Stack Actually Covers

Mostly, it breaks into four jobs that rarely live in one platform: finding targets, tracking the deal and sponsor landscape, running the pipeline, and consolidating the portfolio after close. Trying to force all four into a single generalist tool is the most common reason roll-up tech stacks stall out around the tenth acquisition.

Target identification. Finding which practices, in which specialties and geographies, are actually worth pursuing — ideally before a broker has them in market. In healthcare specifically, this increasingly means claims or provider-affiliation data, not just a company database, since the target is often a single physician group with no public financial footprint.

Deal and sponsor tracking. Knowing who owns what, how long a sponsor has held it, and when a platform company is approaching a typical exit window. This is the traditional private-markets database category — PitchBook, Grata, Dakota Marketplace — extended into healthcare.

Pipeline and relationship management. A CRM built around deal stages, IC memos, and outreach cadence rather than sales quotas. Generalist CRMs like Salesforce can be configured for this; PE-native tools like DealCloud and Meridian are built around it from the start.

Post-close integration. Once an add-on closes, its books, payroll, and billing data need to fold into the platform company’s systems. This is the stage most roll-up tech stacks skip, and the one that determines whether an operating partner has real-time EBITDA visibility or a 20-day close.

Compliance and structuring. Anything touching corporate practice of medicine restrictions, MSO structuring, or state-level transaction review needs its own legal and advisory support — no software tool in this category substitutes for that.

What a Healthcare PE Deal Team’s Week Actually Looks Like

Mostly sourcing and screening early in the week, diligence and IC prep by the end of it. A deal team running an active healthcare roll-up typically spends Monday through Wednesday on market coverage and outbound, then shifts into diligence support and internal reporting as live deals move toward a term sheet or close.

The recurring blocks look roughly like this:

• Market scan. Reviewing new listings, broker outreach, and hold-period signals on sponsor-owned platforms approaching exit, alongside fresh claims or provider data on independent practices.

• Target screening. Qualifying practices against the platform’s thesis — specialty mix, geography, provider count, procedure volume — and ranking them before assigning outreach.

• Owner and broker outreach. Warm and cold contact with practice owners, often run in parallel by an in-house business development function or an outsourced sourcing firm.

• Diligence support. Pulling claims, referral, and payer-mix data to support the deal team’s financial and clinical diligence once a target engages.

• Pipeline and IC reporting. Updating deal stages in the CRM and preparing investment committee materials that show sourcing volume, conversion, and active deal status.

The tooling’s job across all of this is to compress the gap between “this practice exists” and “this practice is qualified, contacted, and in the pipeline” — the same compression a physician liaison’s software does for referral relationships, just running in the opposite direction, toward acquisition instead of retention.

The 8 Best Tools for Healthcare PE Roll-Ups in 2026

1. Alpha Sophia — Best for finding fragmented, physician-level targets before they hit the market

Alpha Sophia is a healthcare commercial intelligence platform built on claims data covering roughly 80% of US medical claims across more than 4 million active providers. For a roll-up sourcing team, that means the ability to identify independent practices and physicians by specialty, procedure volume, and geography directly from billing activity — the layer of the market that generic company databases, built for corporate structures rather than individual providers, typically miss.

The platform includes a built-in CRM with one-click export, an interactive territory map, and Provider API access, so a sourcing team can move from a market map straight into an outreach pipeline without switching tools. It does not track sponsor ownership, hold periods, or deal comps the way a dedicated deal-sourcing database does, which is worth pairing with a tool from the next category if sponsor-to-sponsor activity is part of the thesis.

Best for: healthcare-focused sourcing teams that need to find and rank independent, physician-level targets in fragmented specialties, not just track which companies already have sponsor backing.

2. Grata — Best AI-powered company discovery for fragmented specialty roll-ups

Grata is an AI-powered private markets platform built for sourcing, market mapping, and deal screening, searching across tens of millions of private companies with keyword and filter-based discovery. It has developed particular strength in healthcare roll-ups specifically, with reporting noting it excels at identifying sponsor-backed roll-ups in fragmented specialties like dental and dermatology, and similar micro-cap healthcare verticals.

Grata’s data is built around company-level records rather than individual providers, so it complements rather than replaces a claims-based tool when the target is a solo or small-group physician practice with limited public footprint.

Best for: sourcing teams that want broad, AI-assisted company discovery across a fragmented specialty before narrowing to specific practices.

3. PitchBook — Best for tracking sponsor ownership and deal comps across the healthcare landscape

PitchBook provides ownership, financing history, and valuation data across private equity and venture-backed companies, with screening tools built to identify sponsor-owned healthcare companies and track sponsor activity over time. It is also the primary data source several independent healthcare-PE trackers, including the Private Equity Stakeholder Project, use to compile deal activity each month.

Best for: teams that need deal comps, sponsor history, and exit-timing context alongside their sourcing motion, particularly for sponsor-to-sponsor deals.

4. Dakota Marketplace — Best low-cost database of sponsor-backed healthcare portfolio companies

Dakota Marketplace tracks sponsor-backed and independent private companies with GP ownership data, portfolio history, and sector classification, including a healthcare dataset spanning health management services, healthcare software, and biotech. Its pricing is positioned well below the enterprise private-markets platforms, which makes it a common second or third seat for teams that already have a primary sourcing tool.

Best for: lean deal teams or corp-dev functions that want sponsor-ownership and hold-period visibility without an enterprise data contract.

5. DealCloud (Intapp) — Best enterprise-grade CRM for large, multi-platform roll-up sponsors

DealCloud is a deal and relationship management platform built for private equity, offering no-code dashboard and workflow configuration alongside geospatial deal visualization and AI-assisted relationship mapping. It is positioned at the higher end of implementation complexity and cost among PE CRMs, which tends to suit sponsors running several platform companies and a larger deal team rather than a single lean roll-up.

Best for: sponsors managing multiple healthcare platforms at once who need heavy customization and cross-team reporting.

6. Meridian — Best AI-native CRM for a lean healthcare roll-up deal team

Meridian is a CRM built specifically for private equity and private markets deal teams, positioned as unifying enrichment, contacts, market mapping, and deal initiation in one platform rather than requiring a generic CRM to be heavily configured. It’s built to learn from a firm’s historical deal flow to help surface companies aligned with an existing thesis.

Best for: smaller roll-up sponsors that want PE-native CRM structure without DealCloud’s implementation overhead.

7. Definitive Healthcare — Best for broader provider and facility intelligence layered onto a CRM

Definitive Healthcare is a healthcare commercial intelligence platform whose PhysicianView and facility datasets profile specialties, affiliations, and technology adoption across the provider landscape, with an Atlas All-Payor Claims dataset and Salesforce/HubSpot connectors that push that data directly into a deal team’s existing CRM.

Best for: teams that want provider and facility data enriching a CRM they already run, rather than a standalone sourcing tool.

8. Acumatica — Best cloud ERP for consolidating the books after add-ons close

Acumatica is a cloud ERP platform commonly implemented for PE-backed operators across dental, behavioral health, and physician-group roll-ups, typically through specialist implementation partners rather than direct enterprise contracts. Its core relevance to a roll-up is native multi-entity architecture — consolidated P&L, branch-level accounting, and intercompany eliminations across acquired practices from a single instance, which is the gap that causes fragmented, spreadsheet-driven month-end closes once a portfolio passes a handful of entities.

Best for: operating partners who need every acquired practice’s financials consolidated into one system rather than reconciled by hand after each close.

Comparison Table

Data points reflect each vendor’s public disclosures as of September 2026 and should be confirmed during evaluation — most of these vendors do not publish pricing openly.

What Deal and Market Data Can and Cannot Tell You

Mostly, sourcing and claims data show what a practice looks like on paper, not whether its owner wants to sell or how it will perform once integrated. Procedure volume, payer mix, and provider count from claims data are strong proxies for a practice’s commercial value, but they say nothing about staff retention risk, physician non-competes, or the cultural fit that determines whether an add-on’s providers stay through the first year.

Sponsor-ownership and hold-period data are similarly directional rather than predictive. A platform company approaching a typical five-to-seven-year hold window is a reasonable signal that a sponsor-to-sponsor deal may be coming, but funds extend holds constantly for reasons that have nothing to do with data any outside database can see — a stalled add-on pipeline, a soft exit market, or an LP-specific timing preference.

None of this argues against using the data — it argues for treating a sourcing platform’s output as a ranked list of conversations worth having, not a ranked list of deals worth closing. The programs that get this wrong tend to over-index on a single score or signal instead of pairing the data with the broker relationships and on-the-ground diligence that actually close deals.

How to Choose Tools for a Healthcare Roll-Up

If you are sourcing in a fragmented, physician-owned specialty like dermatology, GI, or dental, a claims-based tool like Alpha Sophia or Grata’s healthcare-focused search will surface targets a generic company database misses entirely.

If your priority is tracking sponsor-to-sponsor activity and exit timing on platforms already in someone else’s portfolio, PitchBook or Dakota Marketplace answer a different question than target sourcing does — who else is already in this market, and when might they sell.

If you are running more than a handful of active deals at once, a PE-native CRM like DealCloud or Meridian will hold up better than a spreadsheet or a generic Salesforce instance configured after the fact.

If you are past the point of closing add-ons and into integrating them, don’t skip the ERP step — a platform company that scales past five or six entities on disconnected books usually finds out how expensive that was at the next LP reporting cycle, not before.

The Short Version

A healthcare roll-up’s tool stack splits into four jobs — find targets, track the market, run the pipeline, consolidate the books — and almost no single platform does all four well. Most sponsors eventually need tools from at least three of those categories, but rarely need to buy all four before the first close.

The category is no longer just about who has the biggest private-company database. It’s about whether the tool finds the physician-owned practice that never shows up in a generic search, before a competing sponsor’s broker calls first.

Want to see which independent practices are worth pursuing in your target specialty? Book a demo and we will map the fragmented, physician-level targets in your thesis directly from claims data.

Frequently Asked Questions

What tools do healthcare private equity roll-ups use?

Healthcare PE roll-ups typically use four kinds of tools across the deal lifecycle: target identification platforms (claims or provider data to find fragmented practices), deal-sourcing databases (sponsor ownership and comps), PE-native CRMs (pipeline and outreach management), and post-close ERP systems (multi-entity financial consolidation once add-ons close).

What is the difference between a PE deal-sourcing tool and a healthcare-specific targeting tool?

A general deal-sourcing tool like Grata or PitchBook finds private companies by industry, size, and ownership signals. A healthcare-specific targeting tool like Alpha Sophia finds individual physicians and practices using claims data, which matters because the best roll-up targets are often single-location, physician-owned practices with no public company footprint to search against.

How many deals are healthcare PE roll-ups actually doing?

The Private Equity Stakeholder Project tracked 1,029 US healthcare PE deals in 2025, including 664 add-on acquisitions across 420 platform companies — meaning roughly two-thirds of all healthcare PE deal activity was small, serial tuck-ins rather than new platform buyouts.

Do healthcare roll-ups need a dedicated CRM?

Most benefit from one once they’re running more than a handful of active deals. Purpose-built PE CRMs like DealCloud and Meridian are built around deal stages, IC reporting, and relationship tracking rather than sales pipeline stages, which tends to hold up better than a spreadsheet or a generically configured CRM as deal volume grows.

Why does post-close ERP matter for a healthcare roll-up?

Once a platform company has acquired several practices, each with its own chart of accounts, billing system, and payroll, consolidating financials by hand becomes slow and error-prone. A multi-entity ERP like Acumatica is built to consolidate P&L and eliminate intercompany transactions across every acquired entity from one system, which is what makes site-level EBITDA reporting fast enough to be useful to an operating partner.

Is private equity investment in healthcare still growing in 2026?

Yes, based on the most recent data. Global healthcare PE deal value hit a record $191 billion in 2025, and analysts at Bain & Company and elsewhere expect continued activity into 2026 given high levels of dry powder and a growing number of sponsor-owned assets reaching typical exit windows.